🔗 Share this article

Given that America continues making unprecedented revisions to its vaccination guidelines, a particular individual has emerged unexpectedly: Høeg, a Danish American physician and epidemiologist who initially gained attention by questioning coronavirus vaccines throughout the global health crisis and has zeroed in on potential deaths following Covid immunization in her brief time at the FDA.

Planned Shifts to Pediatric Vaccine Schedule

Agency leaders were set to announce radical changes to the childhood vaccination calendar earlier this month, bringing the US with the Danish immunization schedule, sources say – a major change that would place the US at odds with much of the world with no evidence for public health gain. This reveal has been delayed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to run the center this calendar year.

Consolidating Power at the FDA

The acting appointment may indicate a tighter collaboration between the drug and biologics divisions as Høeg and Dr. Prasad consolidate power at the FDA – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Høeg has often pushed for ending specific childhood shot schedules in the US in order to be more similar to the Danish model, a society with comprehensive healthcare and a population approximately the population of the state of Wisconsin.

So far statements, she has persisted in emphasizing on vaccines – typically the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Qualifications

Dr. Høeg has no apparent background in drug development, oversight or management, which has been typical for past heads of the biologics center. She has been employed at the FDA as a key advisor to the FDA chief and CBER since March.

“She appears not to have the requisite experience” for leading the CDER, remarked Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in leading a large organization. She is not an expert in pharmaceutical oversight.”

Past directors of the center would “understand legal statutes and the science of drug development”, said Janet Woodcock. “Clearly, she has not acquired the type of experience that prior appointees who headed the center have had.”

This division has an enormous portfolio at the agency, Woodcock pointed out.

“The public just focuses on the new drug program, but the generic drug division approves a multitude of generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and all of those need to be managed,” Dr. Woodcock said. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a major leadership aspect to the job, which supervises over 5,000 personnel. “It is a huge administrative position, if you perform it correctly,” she added.

Response and Disputed Policies

When asked about questions about Høeg’s fitness for the role and whether this appointment represents increased cooperation among FDA leaders on vaccines, a representative responded that the “inquiries rely on inaccurate premises”.

“Her experience matches the duties of her position,” the official stated, pointing to the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a contentious expedited medication authorization process that apparently troubled her predecessors. “How are these therapies being picked for this voucher program? Who takes the choices?” Dr. Howard asked. “There’s a lot of confidentiality happening at the agency right now.”

Overall, he stated, “the agency looks to be trending towards more relaxed regulations of all drugs, aside from vaccines.”

Public Track Record on Vaccines

With immunizations, Høeg has a clearer, if problematic, track record, Howard observe. She authored a research paper using unverified public submissions to estimate the incidence of myocarditis following COVID-19 vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccinations are more dangerous than they are.

Among her “policy goals” for the new government encompassed changing rules for new vaccines and discontinuing “unnecessary” immunizations, she said following the vote on a audio program. At the FDA, Dr. Høeg has reportedly proposed barring young men from getting Covid vaccinations.

“She’s an all-around true believer who begins with her preconceived notions and reverse-engineers to accommodate the data in a very disingenuous, untruthful manner,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|